Ezz Life Science logo

Ezz Life Science(ASX) EZZ

Market CapA$16.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-67%
5 Year-25%
1 Year-86%
1 Month-29%
A$0.36
+2.86%
+0.01Today
Ezz Life Science last closing stock price
MetricPriceDate
Last closeAUD 0.362026-10-09
Ezz Life Science stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.7%AUD 0.372026-10-02
1 month-28.71%AUD 0.512026-09-09
3 month-20%AUD 0.452026-07-10
Year to date-74.47%AUD 1.412025-12-31
1 year-85.98%AUD 2.572025-10-09
3 year-38.44%AUD 0.582023-10-10
5 year-25.45%AUD 0.482021-10-08
Since inception-66.57%AUD 1.052021-03-03

Ezz Life Science Financials at a Glance

Market Cap

A$16.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$113.15M

Net Income (TTM)

A$1.41M

EPS (TTM)

-A$0.11

P/E Ratio

-3.09

Dividend

A$0.02

Beta (Volatility)

0.07 (Low)

Price

A$0.36

Volume

4,269

Open

A$0.36

Previous Close

A$0.36

Daily Range

A$0.36 - A$0.36

52-Week Range

A$0.32 - A$3.38

Estimated Earnings Date

Mar 1, 2027

EZZ News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ezz Life Science

EZZ Life Science Holdings Limited is an Australian biotechnology company specializing in skincare and consumer health products. The company operates in Australia, New Zealand, Mainland China, and other international markets, offering a diverse range of products under its EZZ and EAORON brands.

Products and Services
  • EAORON-branded skincare products available in pharmacies and supermarkets
  • EZZ-branded vitamins, dietary supplements, and sports nutrition products
  • Direct-to-consumer sales through e-commerce platforms like Tmall Global
Growth Outlook
  • Recent quarterly revenue reached AUD 21.46 million, indicating strong market demand
  • TTM gross profit margin stands at 55.68%, showcasing effective cost management
  • Expansion into international markets is expected to drive future revenue growth
Financial Highlights
  • Trailing twelve months (TTM) revenue of AUD 102.5 million reflects consistent performance
  • Current ratio of 8.70 indicates strong liquidity and financial health
  • Dividend yield of 10.81% offers attractive returns to shareholders
EZZ Life Science Holdings Limited has established a solid foundation in the biotechnology sector, focusing on innovative skincare and health products. The company's dual-segment approach, combining wholesale distribution and direct-to-consumer sales, positions it well for future growth. Recent financial performance highlights, including a significant quarterly revenue and a robust gross profit margin, underscore the company's operational efficiency. With a strong liquidity position and an attractive dividend yield, EZZ Life Science Holdings Limited presents a compelling opportunity for potential investors interested in the biotechnology industry.
AI Generated • Oct 3, 2026

Industry

Personal Products

Sector

Consumer Staples

CEO

Qi Zhou Qin

Website

www.ezzlife.com.au

Headquarters

Lidcombe, NSW 2141, AU

EZZ Financials

Key Financial Metrics (TTM)

Gross Margin

55.68%

Operating Margin

-14.28%

Net Income Margin

-11.50%

Return on Equity

-20.36%

Return on Capital

-26.46%

Return on Assets

-19.26%

Earnings Yield

-32.36%

Dividend Yield

5.71%

Payout Ratio

-16.96%

Stock Overview

Market Cap

A$16.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

47.04M

Volume

4.27K

Avg. Volume

15.71K

Financials (TTM)

Gross Profit

A$75.49M

Operating Income

A$7.24M

EBITDA

A$4.32M

Operating Cash Flow

-A$4.39M

Capital Expenditure

-A$273.80K

Free Cash Flow

-A$4.67M

Cash & ST Invst.

A$9.72M

Total Debt

A$478.59K

Ezz Life Science Performance Analysis

Ezz Life Science annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 37,143,330147.3%
20242024-06-30AUD 66,443,37178.9%
20252025-06-30AUD 72,761,1189.5%
20262026-06-30AUD 46,280,283-36.4%
Ezz Life Science sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-32.3%
Q42025-06-3020.8%
Q22025-12-31-32.2%
Q42026-06-30-13.5%
Ezz Life Science annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD 0.09175.1%
20242024-06-30AUD 0.1690.1%
20252025-06-30AUD 0.15-10.0%
20262026-06-30AUD -0.11N/A
Ezz Life Science sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-45.7%
Q42025-06-305.9%
Q22025-12-31-118.2%
Q42026-06-30-631.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$21.46M

-52.0%

Gross Profit

A$10.23M

-70.6%

Gross Margin

47.65%

N/A

Market Cap

A$16.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$1.50M

N/A

Employees

11

N/A

Net Income

-A$4.68M

-180.4%

EBITDA

-A$6.26M

-172.4%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$9.72M

-48.9%

Total Debt

A$478.59K

+286.4%

Accounts Receivable

A$4.96M

+85.4%

Inventory

A$4.02M

+186.9%

Long Term Debt

A$123.86K

N/A

Short Term Debt

A$354.74K

+186.4%

Return on Assets

-19.26%

N/A

Return on Invested Capital

-26.80%

N/A

Free Cash Flow

-A$3.27M

-153.6%

Operating Cash Flow

-A$3.27M

-150.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IMU.AXImugene Limited
A$0.04-7.14%
PCK.AXPainChek Limited
A$0.10-1.04%
ALA.AXArovella Therapeutics Limited
A$0.05+8.33%
ATH.AXAlterity Therapeutics Limited
A$0.36-2.74%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$22.19-9.79%
WFFWf
$7.31+256.54%
VEEAVeea
$5.72+47.80%
SPCXSpace Exploration Technologies
$161.67+0.68%

Questions About EZZ

What is the current price of Ezz Life Science?

Ezz Life Science is trading at A$0.36 per share.

What is the 52-week range for Ezz Life Science?

Over the past 52 weeks, Ezz Life Science has traded between A$0.32 and A$3.38.

How much debt does Ezz Life Science have?

As of the most recent reporting period, Ezz Life Science reported total debt of A$478.59K.

How much cash does Ezz Life Science have on hand?

Ezz Life Science reported A$9.72M in cash and cash equivalents in its most recent financial results.

What is Ezz Life Science’s dividend yield?

Ezz Life Science currently has a dividend yield of 5.71%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services